We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App





New Study Reveals Rapid Sepsis Test Drives 56% Boost in ED Discharges

By LabMedica International staff writers
Posted on 31 Jul 2025

Every year, emergency departments (EDs) in the United States record over 155 million visits, with around 20% of adults showing signs of potentially serious infections. More...

One of the most critical choices emergency clinicians must make is determining which of these patients has sepsis and which do not. In situations where time is of the essence, the ability to swiftly and accurately rule out sepsis can significantly influence patient outcomes, the quality of care, hospital finances, and the overall efficiency of the healthcare system.

At the same time, overcrowding in EDs continues to put pressure on hospital operations and affect patient satisfaction. Over a 12-month span, average ED boarding times rose from 167 to 175 minutes, while the percentage of patients leaving without being seen increased from 1.1% to 2.1%, raising serious safety concerns. In such a context, being overly cautious and admitting patients out of concern for sepsis—though done with good intentions—can worsen crowding and slow down treatment for others, including those who are actually septic. Now, new multicenter study data presented at ADLM 2025 reveal that targeted sepsis testing at triage in the ED may be key to preserving inpatient bed capacity for the most severe patients.

Cytovale’s (San Francisco, CA, USA) IntelliSep is a rapid diagnostic tool for sepsis that supports emergency clinicians in making more confident decisions by quickly assessing patients’ sepsis risk. This U.S. Food and Drug Administration-cleared diagnostic, which provides results in roughly eight minutes from a standard blood draw, can be used at the triage stage to stratify patients based on their risk. The quick results help clinicians distinguish those who can be safely discharged from those needing urgent care and possible hospitalization. The study shared at ADLM 2025 involved 4,650 patients showing signs and symptoms of infection, who were tested with IntelliSep over a four-month period at four hospitals.

Using IntelliSep's rapid host-response test led to a 56% relative increase in discharges from the ED among patients identified as low risk, while simultaneously reducing the use of inpatient beds—without causing a rise in return visits. By applying this risk assessment tool early during triage, clinicians were able to avoid unnecessary admissions and discharge patients more confidently. The findings emphasize that smarter, data-driven sepsis evaluations at triage can have a direct effect on hospital capacity by boosting the number of safe discharge decisions.

Related Links:
Cytovale


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Research has linked platelet aggregation in midlife blood samples to early brain markers of Alzheimer’s (Photo courtesy of Shutterstock)

Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk

Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.